A very long paper which in short asks: Should the exemptions from the Clearing Obligation for a third-country entity which is part of a consolidated group based in the EU, be extended? The answer is almost certainly Yes, but I'll allow you to submit your own feedback.
This paper produces the most detailed analysis I've seen of the state of CCPs and their ability to resist market stress conditions. It also provides an insight into the relative size and strength of global CCPs using a variety of data. The overall conclusion is that CCPs are 'safe' but looking at the anonymised concentration risk charts it is evident that some banks are significant in their inter-connnectedness to the network of CCPs and therefore their impact in a default scenario.
ESMAs review of TRs (as shown in the fact sheet summary below), indicates that clients do not find it easy to compare pricing across TRs. ESMA doesn't offer any action plan at this point, only to share these observations, and perhaps behind the scenes work with TRs to make price comparisons easier.
Much like the SEF mandate in the US, following MIFID II certain OTC products must now trade on an electronic platform, for which the PDF below is the list. Products outside this list can still trade directly by other means.
On 4 May 2017, the European Commission published its legislative proposal for the long-awaited review of Regulation (EU) No 648/2012 of the European Parliament and of the Council of 4 July 2012 on OTC derivatives, central counterparties and trade repositories (‘EMIR’).